RxDoctor Payments Data

Alison Loranger, OD

Optometrist · Hooksett, NHNPI 1003129610

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 31 payments — averaging $42.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$258
  • Bausch & Lomb Americas Inc.$248
  • Glaukos Corporation$223
  • Alcon$120
  • Johnson & Johnson Vision Care, Inc.$119
  • Genentech USA, Inc.$111
  • plus $231 from 7 others

What the payments were for

  • Food & beverage$1,309100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309 in reported general payments places this provider in the 65th percentile of 235 optometrist providers in New Hampshire.

See all optometrist providers in New Hampshire

Medicare billing

Part B allowed, 2024
$167,805
Medicare patients
773
Services billed
2,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine77$77,021
RocklatanNetarsudil Mesylat/Latanoprost55$33,102
Cyclosporine49$21,024
LumiganBimatoprost29$16,022
CequaCyclosporine13$11,422
RhopressaNetarsudil Mesylate18$8,178
Latanoprost722$6,187
CombiganBrimonidine Tartrate/Timolol19$5,455
SimbrinzaBrinzolamide/Brimonidine Tart22$5,084
Travoprost27$4,929
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$4,580
Timolol Maleate326$3,894
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat181$2,525
Brimonidine Tartrate81$2,158
TafluprostTafluprost/Pf24$2,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$67$98,498125 claims
AlconSimbrinza$120$5,08422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 235 optometrist providers in New Hampshire.

Other optometrist in Hooksett

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →